IBX drug formulary updates effective January 1, 2027

Effective January 1, 2027, Independence Blue Cross (IBX) and Independence Administrators will update the Select Drug Program® Formulary and Value Formulary. The changes include updates to the formulary status of several brand-name medications where generic alternatives will be available.

Januvia® and Janumet® [XR]

Effective January 1, 2027, Januvia® and Janumet® [XR] will become non-preferred on the Select Drug Program Formulary and require prior authorization and will become non-formulary on the Value Formulary. Formulary update letters are being sent to impacted members and their providers.

  • Generic alternatives available:

    • Januvia: Sitagliptin

    • Janumet: Sitagliptin and metformin


Januvia and Janumet [XR] are indicated for the treatment of type 2 diabetes mellitus.

Farxiga® and Xigduo® XR

Effective January 1, 2027, Farxiga® and Xigduo® XR will become non-pr​eferred on the Select Drug Program Formulary and require prior authorization and will become non-formulary on the Value Formulary.

  • Generic alternatives available:

    • Farxiga: Dapagliflozin

    • Xigduo XR: Dapagliflozin and metformin


Farxiga and Xigduo XR have indications related to type 2 diabetes mellitus, cardiovascular risk, heart failure, and chronic kidney disease.

Learn more

Providers can review the full formularies on the IBX website, where formularies are available to download as PDFs or search by drug name.

Visit IBX to learn more about our pharmacy policies and programs.

26-0200


​